Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection (2022)
Attributed to:
'REBRACOVID' - multicentre cohort study of the natural history and immunology of COVID-19 in Brazil
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.104293
PubMed Identifier: 36182629
Publication URI: http://europepmc.org/abstract/MED/36182629
Type: Journal Article/Review
Parent Publication: eBioMedicine
ISSN: 2352-3964